Paxlovid and allergy medication can interact in clinically important ways that patients and prescribers need to understand before starting treatment. Paxlovid (nirmatrelvir/ritonavir), authorised by the MHRA for mild to moderate COVID-19 in high-risk adults, contains ritonavir — a potent CYP3A4 inhibitor that can significantly alter the metabolism of several allergy medicines, including certain inhaled corticosteroids and antihistamines. Because Paxlovid is typically started within days of a positive COVID-19 test, there is little time for a thorough medicines review unless patients proactively raise concerns. This article explains which allergy treatments are affected, the level of risk involved, and when to seek professional advice.
Summary: Paxlovid can interact with several allergy medications — particularly inhaled corticosteroids such as fluticasone and budesonide — because its ritonavir component inhibits the CYP3A4 enzyme responsible for metabolising many allergy treatments.
- Ritonavir in Paxlovid is a potent CYP3A4 inhibitor and is responsible for the majority of its drug interactions with allergy medicines.
- Fluticasone and budesonide (inhaled or intranasal) carry the highest interaction risk; beclometasone dipropionate is the preferred lower-risk alternative during the five-day course.
- Cetirizine and levocetirizine are the safest antihistamine choices during Paxlovid treatment, as they are renally excreted with minimal hepatic metabolism.
- Loratadine and fexofenadine interactions are generally of low clinical significance, but patients should be monitored for unexpected side effects.
- Patients on fluticasone or budesonide should be counselled on signs of adrenal insufficiency and steroid excess, and should seek prompt medical review if these occur.
- The Liverpool COVID-19 Drug Interactions checker and the MHRA-approved Paxlovid SmPC are the primary UK references for assessing specific interaction risks.
Table of Contents
- How Paxlovid Works and Who It Is Prescribed For in the UK
- Common Allergy Medications and How They Are Classified
- Known Interactions Between Paxlovid and Allergy Treatments
- Which Antihistamines and Allergy Medicines Are Affected
- Guidance From the MHRA and NHS on Managing These Interactions
- When to Speak to a GP or Pharmacist Before Combining Treatments
- Frequently Asked Questions
Am I eligible for weight loss injections?
Find out whether you might be eligible!
Answer a few quick questions to see whether you may be suitable for prescription weight loss injections (like Wegovy® or Mounjaro®).
- No commitment — just a quick suitability check
- Takes about 1 minute to complete
How Paxlovid Works and Who It Is Prescribed For in the UK
Paxlovid combines nirmatrelvir (a SARS-CoV-2 protease inhibitor) with ritonavir (a CYP3A4 inhibitor used as a pharmacokinetic booster), and is prescribed via NHS CMDUs for high-risk adults with mild to moderate COVID-19.
Paxlovid is an antiviral medication developed by Pfizer and authorised for use in the UK by the Medicines and Healthcare products Regulatory Agency (MHRA). It is indicated for the treatment of mild to moderate COVID-19 in adults who are at high risk of developing severe disease. In the UK, eligibility is defined by NHS England commissioning policy and NICE technology appraisal guidance; treatment is typically initiated through NHS COVID Medicines Delivery Units (CMDUs) or local equivalent services and is not available over the counter.
Paxlovid is a combination product containing two active ingredients: nirmatrelvir and ritonavir. The usual adult regimen is nirmatrelvir 300 mg with ritonavir 100 mg taken twice daily for five days. Treatment should be started as soon as possible and within five days of symptom onset, in line with UK guidance. Nirmatrelvir works by inhibiting a protease enzyme (3CL protease) that the SARS-CoV-2 virus requires to replicate. Ritonavir is included not for its own antiviral effect, but as a pharmacokinetic booster — it inhibits the CYP3A4 enzyme in the liver, which would otherwise break down nirmatrelvir too quickly, thereby maintaining therapeutic drug levels in the bloodstream.
It is this ritonavir component that is responsible for the majority of Paxlovid's drug interactions. Because ritonavir is a potent inhibitor of CYP3A4 — and to a lesser extent other cytochrome P450 enzymes — it can significantly alter the metabolism of many co-administered medicines, including certain allergy treatments.
Worried about interactions with other medications? Speak to one of our pharmacists →
Prescribers are advised to check kidney function before initiating treatment: a dose reduction of nirmatrelvir is required in moderate renal impairment, and Paxlovid is not recommended in severe renal or severe hepatic impairment — consult the MHRA-approved Summary of Product Characteristics (SmPC) for full details. Patients who are immunocompromised, elderly, or have underlying conditions such as diabetes, heart disease, or chronic kidney disease are among those most likely to be offered Paxlovid, and these groups are also more likely to be taking regular medications, making awareness of interactions particularly important.
| Allergy Medication | Interaction Mechanism | Risk Level | Clinical Effect | Advice |
|---|---|---|---|---|
| Fluticasone (inhaled/intranasal) | CYP3A4 inhibition by ritonavir increases fluticasone exposure | Moderate–High | Risk of adrenal suppression, Cushing's syndrome | Consider switching to beclometasone for 5-day course; seek clinician advice |
| Budesonide (inhaled/intranasal) | CYP3A4 inhibition by ritonavir increases budesonide exposure | Moderate | Risk of systemic corticosteroid effects, adrenal suppression | Consider switching to beclometasone; monitor for steroid excess symptoms |
| Beclometasone dipropionate | Lower CYP3A4 dependence; minimal interaction with ritonavir | Low | Minimal systemic corticosteroid accumulation expected | Preferred inhaled/intranasal corticosteroid during Paxlovid course per SmPC |
| Cetirizine / Levocetirizine | Renally excreted; minimal hepatic CYP3A4 metabolism | Very Low | No clinically significant interaction expected | Preferred antihistamine choice during Paxlovid treatment |
| Loratadine | CYP3A4 and CYP2D6 substrate; ritonavir may modestly raise levels | Low | Slight increase in plasma levels; possible headache | No routine dose adjustment required; monitor for unusual side effects |
| Chlorphenamine / Promethazine | CYP2D6 and CYP3A4 inhibition by ritonavir may increase levels | Low–Moderate | Enhanced sedation, especially in elderly patients | Use with caution; do not drive or operate machinery if drowsy |
| Montelukast | CYP2C8 and CYP3A4 substrate; minor exposure change possible | Low | No clinically significant interaction expected | Continue usual dose; monitor for neuropsychiatric symptoms per MHRA guidance |
Common Allergy Medications and How They Are Classified
Allergy medicines range from antihistamines and inhaled corticosteroids to biologics; those metabolised by CYP3A4 — such as fluticasone and loratadine — carry the greatest potential for interaction with Paxlovid.
Allergy medications encompass a broad range of treatments used to manage conditions such as allergic rhinitis, urticaria (hives), asthma, food allergies, and anaphylaxis. Understanding how these medicines are classified helps clarify which ones may interact with Paxlovid.
Antihistamines are the most widely used allergy medicines and are divided into two generations:
-
First-generation antihistamines (e.g., chlorphenamine, promethazine) — these cross the blood-brain barrier and are associated with sedation. Their metabolism involves CYP2D6 and, to varying degrees, CYP3A4, though pathways differ between individual agents.
-
Second-generation antihistamines (e.g., cetirizine, loratadine, fexofenadine) — these are generally non-sedating and have varying metabolic profiles. Loratadine is metabolised by CYP3A4 and CYP2D6, whereas cetirizine and levocetirizine are largely excreted unchanged by the kidneys with minimal hepatic metabolism.
Beyond antihistamines, allergy management may also involve:
-
Intranasal or inhaled corticosteroids (e.g., fluticasone, budesonide, beclometasone) — used for allergic rhinitis and asthma
-
Leukotriene receptor antagonists (e.g., montelukast) — used in asthma and allergic rhinitis
-
Oral corticosteroids (e.g., prednisolone) — used for severe allergic reactions
-
Adrenaline auto-injectors (e.g., EpiPen and other brands) — used in anaphylaxis
Some allergy and asthma medicines are metabolised through the liver's cytochrome P450 system, particularly CYP3A4 — the same pathway inhibited by ritonavir — and these carry the greatest potential for interaction. However, not all allergy treatments are affected in this way. Intranasal decongestants such as xylometazoline and oxymetazoline have minimal systemic absorption and are not expected to interact with Paxlovid. Ocular antihistamines and sodium cromoglicate eye drops also have negligible systemic exposure. Biologic therapies used for severe asthma or allergy (e.g., omalizumab, mepolizumab, dupilumab) are not metabolised via cytochrome P450 pathways and are not expected to interact with Paxlovid. For any specific product, checking the BNF or the Liverpool COVID-19 Drug Interactions checker is recommended.
Known Interactions Between Paxlovid and Allergy Treatments
Fluticasone and budesonide carry the most clinically significant interaction risk with Paxlovid; ritonavir inhibits their CYP3A4-mediated metabolism, raising the risk of systemic corticosteroid effects including adrenal suppression.
The primary concern with Paxlovid and allergy medication centres on ritonavir's inhibition of CYP3A4. When this enzyme is inhibited, drugs that rely on it for metabolism can accumulate to higher-than-intended plasma concentrations, potentially increasing both their therapeutic effects and their risk of adverse effects.
Experiencing these side effects? Our pharmacists can help you navigate them →
Intranasal and inhaled corticosteroids represent one of the most clinically significant interaction categories. Fluticasone propionate — widely used in products such as Flixonase nasal spray and Flixotide inhaler — is extensively metabolised by CYP3A4. When co-administered with ritonavir, plasma concentrations of fluticasone can rise substantially, increasing the risk of systemic corticosteroid effects such as adrenal suppression and, in rare cases, Cushing's syndrome. This interaction is well-documented and flagged in the Paxlovid SmPC and in MHRA Drug Safety Update guidance on ritonavir and CYP3A4-metabolised corticosteroids.
It is important to note that with a short five-day Paxlovid course, the risk of clinically significant adrenal suppression from inhaled or intranasal corticosteroids is considered low — but it cannot be excluded, particularly with higher-dose fluticasone or in patients already at risk. Caution is therefore still warranted.
Budesonide carries a similar interaction risk, as does triamcinolone, which is also extensively metabolised by CYP3A4 and should be avoided or used with caution alongside ritonavir. In contrast, beclometasone dipropionate is less dependent on CYP3A4 for its metabolism and is considered to carry a lower interaction risk; it is listed in the Paxlovid SmPC as a preferred alternative inhaled or intranasal corticosteroid during the treatment course.
For oral corticosteroids, the Paxlovid SmPC notes that prednisolone (or prednisone) may be used as a preferred systemic corticosteroid alternative where one is needed during treatment, as it has lower CYP3A4 dependence than some other agents. Clinicians should nonetheless be aware of partial CYP3A4 involvement and monitor accordingly.
Patients taking inhaled or intranasal fluticasone or budesonide alongside Paxlovid should be counselled about potential signs of systemic steroid excess — such as facial rounding, easy bruising, or unusual weight gain — and of adrenal insufficiency, including severe fatigue, nausea, dizziness, or collapse. Any new or concerning symptoms should prompt prompt medical review.
Which Antihistamines and Allergy Medicines Are Affected
Cetirizine and levocetirizine are least likely to interact with Paxlovid due to renal excretion; loratadine and fexofenadine interactions are of low clinical significance, while first-generation antihistamines should be used with caution.
Among antihistamines, the interaction risk varies considerably depending on the specific agent and its metabolic pathway.
Loratadine is metabolised by CYP3A4 and CYP2D6. Co-administration with ritonavir may modestly increase loratadine plasma levels, potentially leading to a slightly higher incidence of side effects such as headache. This interaction is generally considered to be of low clinical significance, and routine dose adjustment is not usually required, though patients should be aware of any unusual symptoms.
Fexofenadine is a substrate of both P-glycoprotein (P-gp) and organic anion transporting polypeptides (OATPs), rather than CYP3A4. Ritonavir inhibits P-gp, which may increase fexofenadine exposure, but ritonavir also inhibits OATP1A2, which can reduce fexofenadine absorption. The net effect on fexofenadine levels is therefore uncertain and may result in either increased or decreased exposure. In practice, this interaction is considered to be of low clinical significance; no routine dose adjustment is required, but patients should be monitored for both reduced efficacy and any unexpected side effects.
Cetirizine and levocetirizine are renally excreted with minimal hepatic metabolism, making them among the least likely antihistamines to interact with Paxlovid. These are often considered the safest antihistamine choices during the treatment course.
Chlorphenamine and promethazine (first-generation antihistamines) involve CYP2D6 and CYP3A4 metabolism to varying degrees. Ritonavir's inhibition of these pathways may increase sedative effects. These agents should be used with caution, particularly in elderly patients. Patients taking sedating antihistamines should follow standard UK advice: do not drive or operate machinery if you feel drowsy.
Regarding montelukast, it is primarily metabolised by CYP2C8 and CYP3A4. Based on current evidence, no clinically significant interaction with ritonavir is expected, and patients should continue their usual dose. Exposure may change slightly, but this is not considered clinically important. Patients should nonetheless continue to be monitored for neuropsychiatric symptoms — such as mood changes, sleep disturbances, or unusual behaviour — as these are a recognised concern with montelukast regardless of Paxlovid, as highlighted in MHRA Drug Safety Update guidance.
Guidance From the MHRA and NHS on Managing These Interactions
The MHRA-approved Paxlovid SmPC and the Liverpool COVID-19 Drug Interactions checker are the primary UK resources; clinicians may switch fluticasone or budesonide to beclometasone and should prefer cetirizine for antihistamine use during treatment.
The MHRA-approved Paxlovid SmPC provides a detailed list of known and potential drug interactions and is the primary UK reference for prescribers. Healthcare professionals initiating Paxlovid are advised to conduct a thorough medicines reconciliation before starting treatment, reviewing all prescribed, over-the-counter, and herbal medicines the patient is taking. The Liverpool COVID-19 Drug Interactions checker (covid19-druginteractions.org), which is widely used and endorsed by NHS clinicians, provides an up-to-date, evidence-based traffic-light categorisation of interactions and is a valuable resource for both prescribers and pharmacists.
The following practical approaches are recommended for managing interactions with allergy medications, consistent with the Paxlovid SmPC and NHS guidance:
-
Switching inhaled or intranasal corticosteroids: Where a patient is using fluticasone or budesonide, clinicians may consider temporarily switching to beclometasone dipropionate for the duration of the five-day Paxlovid course, as it carries a lower interaction risk. This switch should be guided by a clinician or pharmacist.
-
Preferred systemic corticosteroid: Where a systemic corticosteroid is required during the Paxlovid course, prednisolone is listed in the SmPC as a preferred option.
-
Avoiding unnecessary dose increases: Patients should not increase their allergy medication doses during the Paxlovid course without medical advice.
-
Monitoring for corticosteroid side effects: Patients on inhaled or intranasal fluticasone should be counselled about signs of adrenal insufficiency (e.g., severe fatigue, nausea, dizziness, collapse) and steroid excess (e.g., facial rounding, easy bruising). They should seek medical attention promptly if these occur, even though the risk with a five-day course is low.
-
Preferring renally cleared antihistamines: Where antihistamine use is necessary, cetirizine or levocetirizine may be preferred due to their minimal hepatic metabolism.
Patients are encouraged to use the NHS 111 service or consult their GP or pharmacist if they are uncertain about their specific combination of medicines. Suspected side effects from Paxlovid or any other medicine should be reported to the MHRA via the Yellow Card Scheme at yellowcard.mhra.gov.uk or through the Yellow Card app.
When to Speak to a GP or Pharmacist Before Combining Treatments
Patients taking fluticasone, budesonide, combination inhalers, montelukast, or first-generation antihistamines should contact their GP, pharmacist, or NHS 111 before starting Paxlovid to review their medicines and arrange any necessary adjustments.
Given the complexity of Paxlovid's interaction profile, it is strongly advisable for patients to seek professional guidance before combining it with any allergy medication — even those available without a prescription. This is particularly important because Paxlovid is typically initiated quickly after a positive COVID-19 test, and patients may not have the opportunity for a full medicines review unless they proactively raise the issue.
You should contact your GP, NHS 111, or a pharmacist promptly if:
-
You are taking a regular inhaled or intranasal corticosteroid such as fluticasone (e.g., Flixonase, Avamys, Flixotide) or budesonide
-
You are using a combination inhaler containing fluticasone (e.g., Seretide, Relvar)
-
You take montelukast daily for asthma or allergic rhinitis
-
You regularly use first-generation antihistamines such as chlorphenamine or promethazine
-
You have been prescribed oral corticosteroids for an allergic condition
-
You are unsure whether any of your allergy medicines are affected
Pharmacists in the UK are highly trained in drug interactions and can provide rapid, accessible advice — including recommending temporary switches or adjustments for the duration of treatment. They can access resources such as the Liverpool COVID-19 Drug Interactions checker and the BNF to provide evidence-based guidance.
In an emergency — anaphylaxis: If you experience symptoms of a severe allergic reaction such as difficulty breathing, throat swelling, or sudden dizziness or collapse, use your adrenaline auto-injector immediately and call 999. Do not delay emergency treatment because of concerns about Paxlovid interactions. Paxlovid does not preclude the use of adrenaline auto-injectors.
Patients should never stop a prescribed allergy or asthma medication without medical advice, as this could lead to uncontrolled symptoms or a serious allergic reaction. The goal is always to find the safest possible approach that allows Paxlovid to be taken effectively whilst minimising interaction risks. Open communication with your healthcare team remains the most important step in managing these treatments safely.
Frequently Asked Questions
Can I take cetirizine or loratadine whilst on Paxlovid?
Cetirizine and levocetirizine are considered the safest antihistamine options during Paxlovid treatment, as they are renally excreted with minimal CYP3A4 involvement. Loratadine may be used but could have slightly increased plasma levels; this is generally of low clinical significance, though you should speak to a pharmacist if you are unsure.
Is it safe to use a fluticasone nasal spray or inhaler whilst taking Paxlovid?
Fluticasone is extensively metabolised by CYP3A4, which ritonavir in Paxlovid inhibits, potentially raising fluticasone levels and increasing the risk of adrenal suppression. Clinicians may recommend temporarily switching to beclometasone dipropionate for the five-day course; always seek advice from your GP or pharmacist before making any changes.
Should I stop my allergy medication before starting Paxlovid?
You should never stop a prescribed allergy or asthma medication without medical advice, as this could trigger uncontrolled symptoms or a serious allergic reaction. Instead, contact your GP, pharmacist, or NHS 111 promptly so they can review your medicines and advise on any necessary adjustments for the duration of the Paxlovid course.
The health-related content published on this site is based on credible scientific sources and is periodically reviewed to ensure accuracy and relevance. Although we aim to reflect the most current medical knowledge, the material is meant for general education and awareness only.
The information on this site is not a substitute for professional medical advice. For any health concerns, please speak with a qualified medical professional. By using this information, you acknowledge responsibility for any decisions made and understand we are not liable for any consequences that may result.
Any third-party brands or services referenced on this site are included for informational purposes only; we are entirely independent and have no affiliation, partnership, or collaboration with any companies mentioned.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Heading 6
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur.
Block quote
Ordered list
- Item 1
- Item 2
- Item 3
Unordered list
- Item A
- Item B
- Item C
Bold text
Emphasis
Superscript
Subscript
